Repligen Co. (NASDAQ:RGEN) Stock Holdings Lowered by HighTower Advisors LLC

HighTower Advisors LLC lessened its position in Repligen Co. (NASDAQ:RGEN) by 13.1% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,234 shares of the biotechnology company’s stock after selling 788 shares during the period. HighTower Advisors LLC’s holdings in Repligen were worth $773,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Champlain Investment Partners LLC increased its stake in shares of Repligen by 149.0% in the third quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock valued at $211,464,000 after purchasing an additional 850,345 shares during the period. Thrivent Financial for Lutherans increased its position in Repligen by 240.5% in the 2nd quarter. Thrivent Financial for Lutherans now owns 601,829 shares of the biotechnology company’s stock valued at $75,866,000 after acquiring an additional 425,061 shares during the period. Bank of New York Mellon Corp increased its position in Repligen by 21.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock valued at $172,749,000 after acquiring an additional 237,884 shares during the period. Conestoga Capital Advisors LLC raised its stake in Repligen by 26.7% during the 2nd quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock valued at $119,363,000 after acquiring an additional 199,322 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in Repligen by 39.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 429,524 shares of the biotechnology company’s stock worth $54,149,000 after acquiring an additional 121,305 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Repligen Price Performance

Shares of NASDAQ:RGEN opened at $147.34 on Thursday. The company has a market capitalization of $8.26 billion, a PE ratio of -398.21, a price-to-earnings-growth ratio of 4.64 and a beta of 0.96. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The stock has a fifty day moving average of $143.61 and a 200-day moving average of $141.74. Repligen Co. has a one year low of $113.50 and a one year high of $211.13.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.34 by $0.09. The business had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. Repligen’s revenue was up 9.7% compared to the same quarter last year. During the same period in the prior year, the business posted $0.23 earnings per share. As a group, equities analysts anticipate that Repligen Co. will post 1.54 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on RGEN. StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a report on Friday, November 22nd. Royal Bank of Canada reissued an “outperform” rating and set a $205.00 target price on shares of Repligen in a research note on Thursday, September 26th. Canaccord Genuity Group began coverage on shares of Repligen in a research note on Tuesday. They issued a “hold” rating and a $165.00 price target for the company. Canaccord Genuity Group started coverage on shares of Repligen in a research note on Tuesday. They set a “hold” rating and a $165.00 price objective on the stock. Finally, Wolfe Research started coverage on Repligen in a research report on Thursday, November 14th. They issued a “peer perform” rating for the company. Six equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, Repligen presently has a consensus rating of “Moderate Buy” and a consensus target price of $185.20.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.